Creative Medical Technology Acquires Majority Stake in BioDefense for $200k and 1M Shares

Creative Medical Technology Holdings, Inc. entered into a Stock Purchase Agreement on September 24, 2026, to acquire 4,000,000 shares of BioDefense, Inc. common stock from Creative Acquisition Corp. (CAC). The transaction was valued at an aggregate purchase price of $200,000 in cash and 1,000,000 shares of Creative Medical Technology’s common stock.

Following the closing of this transaction, Creative Medical Technology now owns 16,000,000 shares of BioDefense common stock, representing 80% of the company’s outstanding shares. CAC retains 4,000,000 shares, which constitutes the remaining 20% ownership stake.

The shares of Creative Medical Technology common stock issued to CAC were distributed in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933. The filing notes that Timothy Warbington serves as the President and Chief Executive Officer of Creative Medical Technology and is also the Chairman and Chief Executive Officer of CAC. Additionally, Mr. Warbington indirectly owns all of the outstanding shares of CAC’s capital stock.